Aquinox Pharmaceuticals Announces Results From Phase 2 KINSHIP Trial With AQX-1125 in Patients With Atopic Dermatitis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Aquinox Pharma (AQXP) Reports Negative KINSHIP Trial Data; Cowen Maintains Outperform
November 3, 2015 2:22 PM ESTCowen maintained an Outperform rating on Aquinox Pharmaceutical (NASDAQ: AQXP), and cut the price target to $23.00 (from $24.00), following negative KINSHIP trial data. The KINSHIP trial demonstrated AQX-1125 to be well tolerated and adverse events were consistent with prior clinical trials. No serious adverse... More
Needham & Company Keeps Aquinox Pharma (AQXP) at 'Buy'; Failure of AQX-1125 in Atopic Dermatitis Won't Impact Model
November 3, 2015 9:48 AM ESTNeedham & Company affirms Aquinox Pharma (Nasdaq: AQXP) with a Buy rating and $25 price target after the company... More
Aquinox Pharma's (AQXP) Phase 2 KINSHIP Trial With AQX-1125 Fails to Demonstrate Efficacy
November 3, 2015 6:36 AM ESTAquinox Pharmaceuticals, Inc. (Aquinox) (Nasdaq: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today its Phase 2 KINSHIP clinical trial failed to demonstrate efficacy in patients with mild to moderate atopic dermatitis.
"We believe that... More
